Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in cash, cash equivalents and investments - - Company to host …